• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of infection and chemotherapy: official journal of the Japan Society of Chemotherapy >Investigation of pneumonia-causing pathogenic organisms in children and the usefulness of tebipenem pivoxil for their treatment.
【24h】

Investigation of pneumonia-causing pathogenic organisms in children and the usefulness of tebipenem pivoxil for their treatment.

机译：对儿童中引起肺炎的致病菌进行调查，以及替比培南和匹伐西汀在治疗中的作用。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

We investigated the usefulness of the novel oral carbapenem antibiotic tebipenem pivoxil (TBPM-PI) for treating bacterial pneumonia in children. Sputum and nasopharyngeal swabs were collected simultaneously, and causative organisms were identified by conventional bacterial culture together with exhaustive bacterial and viral identification by real-time polymerase chain reaction (PCR). The subjects were eight patients diagnosed with mild or moderate pneumonia at Sotobo Children's Clinic Outpatient Department between October 2006 and June 2007. TBPM-PI was administered at the recommended clinical dose of 4 mg/kg b.i.d. to five patients and at a high dose of 6 mg/kg b.i.d. to three patients. Sputum was collected from all patients, and 11 strains were detected from washed sputum culture. Causative organisms were mainly Streptococcus pneumoniae (3 strains) and Haemophilus influenzae (6 strains), and nasopharyngeal swabs showed the same organisms as coughed-up sputum. Real-time PCR for individual viruses and Mycoplasma pneumoniae identified four cases of only bacterial infection, one case of M. pneumoniae coinfection, two cases of viral coinfection, and one case of both viral and M. pneumoniae coinfection. The clinical results indicated efficacy in all patients, and causative organisms were 100% eliminated. In the four patients with only bacterial infection, the average fever of 38.9 degrees C at the start of treatment normalized the following day, showing excellent efficacy. No clinically problematic adverse events occurred, and compliance was good. We consider that these cases provide valuable insights into the identity of pathogenic organisms of pneumonia in children and the possible role of TBPM-PI in outpatient treatment.
机译：我们调查了新型口服碳青霉烯类抗生素替比农仑匹伏西尔（TBPM-PI）在治疗儿童细菌性肺炎中的作用。同时收集痰和鼻咽拭子，并通过常规细菌培养鉴定致病菌，并通过实时聚合酶链反应（PCR）鉴定详尽的细菌和病毒。受试者为2006年10月至2007年6月间在Sotobo儿童诊所门诊诊断为轻度或中度肺炎的八名患者。TBPM-PI的建议临床剂量为4 mg / kgb.i.d。以5 mg / kg b.i.d的高剂量治疗5例患者。给三个病人。从所有患者中收集痰液，并从洗过的痰液培养物中检测到11个菌株。致病菌主要为肺炎链球菌（3株）和流感嗜血杆菌（6株），鼻咽拭子显示与咳嗽痰相同的微生物。实时荧光定量PCR可以鉴定出4例仅细菌感染的病例，1例肺炎支原体合并感染，2例病毒合并感染以及1例病毒和肺炎支原体合并感染。临床结果表明对所有患者均有效，并且消除了病原体100％。在仅有细菌感染的四名患者中，第二天开始治疗时平均发烧38.9摄氏度，显示出优异的疗效。没有发生临床上有问题的不良事件，依从性良好。我们认为这些案例为儿童肺炎的病原体鉴定以及TBPM-PI在门诊治疗中的可能作用提供了有价值的见解。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号